I need to re-read the filing carefully. The balance sheet data IS present in the filing text. Let me verify each figure: - Cash and cash equivalents: $72,054 (June 30, 2026) - confirmed - Short-term investments: $0 (June 30, 2026) / $73,837 (Dec 31, 2025) - confirmed - Total assets: $106,412 (June 30, 2026) - confirmed - Total liabilities: $67,941 (June 30, 2026) - confirmed - Contract liabilities (long-term): $55,218 (June 30, 2026) - confirmed The previous QA reviewer flagged these as "unsupported" but they are directly in the filing. I must include them accurately. The forward-looking statement about 2028 funding is listed in the filing's forward-looking statements section, so I can reference it as the company's own forward-looking statement subject to its cautionary language.

Silence Therapeutics plc (Nasdaq: SLN), a clinical-stage RNA medicine company incorporated in England and Wales, filed its quarterly report on Form 10-Q for the period ended June 30, 2026, with the U.S. Securities and Exchange Commission on August 10, 2026.

Key Highlights

  • Ordinary shares outstanding: As of July 31, 2026, the company had 141,740,037 ordinary shares outstanding, including shares in the form of American Depositary Shares, at a nominal value of £0.05 per share.
  • Cash position shift: Cash and cash equivalents stood at $72,054 thousand as of June 30, 2026, compared with $11,277 thousand as of December 31, 2025.
  • Short-term investments: Short-term investments were $0 as of June 30, 2026, down from $73,837 thousand as of December 31, 2025.
  • Total assets: Total assets were $106,412 thousand as of June 30, 2026, compared with $131,442 thousand as of December 31, 2025.
  • Contract liabilities: Long-term contract liabilities were $55,218 thousand as of June 30, 2026, compared with $55,454 thousand as of December 31, 2025.
  • Filer status: The company is classified as a non-accelerated filer and a smaller reporting company for purposes of this filing.

Balance Sheet Position and Key Financial Data for Silence Therapeutics as of June 30, 2026

According to the condensed consolidated balance sheets included in the filing, Silence Therapeutics reported total assets of $106,412 thousand as of June 30, 2026, a decrease from $131,442 thousand as of December 31, 2025. The company's cash and cash equivalents rose to $72,054 thousand from $11,277 thousand over the same period, while short-term investments fell to $0 from $73,837 thousand, reflecting a shift in the composition of liquid assets rather than an overall increase in total current assets, which moved from $118,658 thousand to $94,281 thousand.

Total liabilities were reported at $67,941 thousand as of June 30, 2026, compared with $69,138 thousand as of December 31, 2025, according to the filing. Long-term contract liabilities, which the filing addresses separately in Note 7, were $55,218 thousand as of June 30, 2026, compared with $55,454 thousand at year-end 2025. Current contract liabilities were $0 at June 30, 2026, versus a credit balance of $168 thousand as of December 31, 2025. Trade and other payables stood at $12,611 thousand as of June 30, 2026, compared with $13,356 thousand at December 31, 2025.

Silence Therapeutics is incorporated in England and Wales and lists American Depositary Shares on The Nasdaq Stock Market LLC under the trading symbol SLN, with each ADS representing three ordinary shares at a nominal value of £0.05 per share. The filing also notes, as a forward-looking statement subject to the company's cautionary language, the company's belief that existing cash and cash equivalents will be sufficient to fund operating expenses and capital expenditure requirements into 2028. The company's principal executive offices are located at 12 Hammersmith Grove, London, United Kingdom W6 7AP.

What Was Disclosed

Silence Therapeutics plc submitted its Form 10-Q for the quarterly period ended June 30, 2026, reporting condensed consolidated balance sheet data, share count information, filer classification, and forward-looking statements subject to the company's stated cautionary language and risk factors.